• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Clarivate Reports First Quarter 2024 Results

    5/8/24 6:00:00 AM ET
    $CLVT
    EDP Services
    Technology
    Get the next $CLVT alert in real time by email

    — Reaffirms 2024 Outlook —

    LONDON, May 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024.

    (PRNewsfoto/Clarivate Analytics)

    First Quarter 2024 Financial Highlights

    • Revenues of $621.2 million decreased 1.3%
    • Organic revenues decreased 1.7%, as an increase in subscription revenues of 2.4% was more than offset by a decrease in transactional and other revenues of 11.4% and re-occurring revenues of 5.1%
    • Net loss attributable to ordinary shares of $93.8 million; Net loss per diluted share of $0.14
    • Adjusted net income(1) of $103.5 million decreased 20.9%; Adjusted diluted EPS(1) of $0.14 decreased 22.2% or $0.04
    • Adjusted EBITDA(1) of $236.3 million decreased 6.5%; Adjusted EBITDA margin(1) of 38.0% decreased 220 basis points primarily due to lower revenues
    • Net cash provided by operating activities of $176.2 million decreased $51.3 million; Free cash flow(1) of $111.8 million decreased $56.4 million primarily due to the timing of working capital

    "We are making great progress this year on key objectives including product investments and operational initiatives to drive future organic revenue growth," said Jonathan Gear, Chief Executive Officer. "Our Intellectual Property segment refined its go-to-market operating model and revived patent intelligence solutions, which is resulting in commercial success across our software solutions, particularly IPFolio, and improved Derwent renewal rates. We released a new real-world data framework in the Life Sciences & Healthcare segment and were awarded deals with two top-10 global pharmaceutical clients. Additionally, we recently acquired two startup companies, MotionHall and Global QMS, Inc. which will enhance our portfolio and expertise in the LS&H segment. We continue to make the necessary improvements to revitalize Clarivate and drive enhanced value for clients, colleagues, and shareholders."

    Selected Financial Information



    Three Months Ended

    March 31,



    Change

    (In millions, except percentages and per share data), (unaudited)

    2024



    2023



    $



    %

    Revenues

    $      621.2



    $     629.1



    $        (7.9)



    (1.3) %

















    Net income (loss) attributable to ordinary shares

    $      (93.8)



    $       24.7



    $    (118.5)



    N/M

    Net income (loss) per share, diluted

    $      (0.14)



    $       0.04



    $      (0.18)



    N/M

    Weighted-average ordinary shares (diluted)

    666.9



    679.3



    (12.4)



    (1.8) %

    Adjusted EBITDA(1)

    $      236.3



    $     252.7



    $      (16.4)



    (6.5) %

















    Adjusted net income(1)

    $      103.5



    $     130.9



    $      (27.4)



    (20.9) %

    Adjusted diluted EPS(1)(2)

    $        0.14



    $       0.18



    $      (0.04)



    (22.2) %

    Adjusted weighted-average ordinary shares (diluted)(1)

    727.6



    734.7



    (7.0)



    (1.0) %

    Net cash provided by operating activities

    $      176.2



    $     227.5



    $      (51.3)



    (22.5) %

    Free cash flow(1)

    $      111.8



    $     168.2



    $      (56.4)



    (33.5) %

    First Quarter 2024 Commentary

    Revenues for the first quarter decreased $7.9 million, or 1.3%, to $621.2 million. Organic revenues decreased $10.5 million or 1.7%.

    Subscription revenues for the first quarter increased $9.9 million, or 2.5%, to $403.1 million. Organic subscription revenues increased 2.4%, driven by price increases.

    Re-occurring revenues for the first quarter decreased $5.2 million, or 4.8%, to $102.5 million. Organic re-occurring revenues decreased 5.1%, primarily due to lower IP patent renewal volumes.

    Transactional and other revenues for the first quarter decreased $12.6 million, or 9.8%, to $115.6 million. Organic transactional and other revenues decreased 11.4%, due to lower A&G volumes and LS&H real world data sales.

    Balance Sheet and Cash Flow

    As of March 31, 2024, cash and cash equivalents of $361.8 million decreased $8.9 million compared to December 31, 2023.

    The Company's total debt outstanding as of March 31, 2024 was $4,722.6 million, a decrease of $47.7 million compared to December 31, 2023, driven by an accelerated debt repayment.

    Net cash provided by operating activities of $176.2 million for the three months ended March 31, 2024 decreased $51.3 million compared to $227.5 million for the prior year period, primarily due to timing differences in working capital. Free cash flow(1) for the three months ended March 31, 2024, was $111.8 million, a decrease of $56.4 million compared to the prior year period.

    Reaffirmed Outlook for 2024 (forward-looking statement)

    "With first quarter results in line with our expectations, we reaffirm our 2024 full year outlook," said Jonathan Collins, Executive Vice President and Chief Financial Officer. "Currently, we anticipate a sequential improvement in organic revenue growth in the second quarter compared to the first quarter. For the full year, we continue to expect to deliver improved growth across our three segments driven by the benefit of product investments and modestly improving market conditions."

    The full year outlook presented below assumes no further acquisitions, divestitures, or unanticipated events.



    2024 Outlook

    Revenues

    $2.57B to $2.67B

    Organic revenue growth

    0% to 2%

    Adjusted EBITDA(1)

    $1.055B to $1.115B

    Adjusted EBITDA margin(1)    

    41% to 42%

    Adjusted diluted EPS(1)(2)

    $0.70 to $0.80

    Free cash flow(1)

    $420M to $500M

    Notes to earnings press release

    (1) Non-GAAP measure. Please see "Reconciliations to Certain Non-GAAP Measures" in this earnings release for important disclosures and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this earnings release.

    (2) Adjusted diluted EPS for 2024 is calculated based on approximately 730 million fully diluted weighted average ordinary shares outstanding.

    N/M - Represents a change approximately equal or in excess of 100% or not meaningful.

    Conference Call and Webcast

    Clarivate will host a conference call and webcast today to review the results for the first quarter at 9:00 a.m. Eastern Time. The webcast is open to all interested parties and may include forward-looking information.

    The live webcast of the earnings call will be accessible through the investor relations section of the Company's website. To join the webcast please visit https://events.q4inc.com/attendee/319586540.

    Interested parties may access the live audio broadcast by dialing +1 404-975-4839 or toll-free +1 833-470-1428 (in North America) and +44 208 068 2558 or toll free +44 808 189 6484 (internationally). The conference ID number is 143104.

    A replay of the webcast will also be available on https://ir.clarivate.com beginning two hours after the conclusion of the live call, and will remain available for one year.

    Use of Non-GAAP Financial Measures

    Non-GAAP results are financial measures that are not prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and are presented only as a supplement to our financial statements based on GAAP. Non-GAAP financial information is provided to enhance the reader's understanding of our financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP. They are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.

    We use non-GAAP measures in our operational and financial decision-making. We believe that such measures allow us to focus on what we deem to be a more reliable indicator of ongoing operating performance and our ability to generate cash flow from operations, and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. These measures can be useful in evaluating our performance against our peer companies because we believe the measures provide users with valuable insight into key components of GAAP financial disclosures. However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies.

    Definitions and reconciliations of non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITDA margin, Adjusted net income, Adjusted diluted EPS, and Free cash flow to the most directly comparable GAAP measures are provided within the schedules attached to this release. Our presentation of non-GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all.

    Forward-Looking Statements

    This communication includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements" within the meaning of the "safe harbor provisions" of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "seeks," "projects," "intends," "plans," "may," "will," or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts, and include statements regarding our intentions, beliefs, or current expectations concerning, among other things, anticipated cost savings, results of operations, financial condition, liquidity, prospects, growth, strategies, and the markets in which we operate. Such forward-looking statements are based on available current market material and management's expectations, beliefs, and forecasts concerning future events impacting us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors of our annual report on Form 10-K. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.

    About Clarivate

    Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.

    Condensed Consolidated Balance Sheets (Unaudited)



    (In millions)

    March 31, 2024



    December 31, 2023

    ASSETS







    Current assets:







    Cash and cash equivalents, including restricted cash

    $                      361.8



    $                   370.7

    Accounts receivable, net

    822.9



    908.3

    Prepaid expenses

    100.0



    88.5

    Other current assets

    67.9



    68.0

    Assets held for sale

    38.2



    26.7

    Total current assets

    1,390.8



    1,462.2

    Property and equipment, net

    49.2



    51.6

    Other intangible assets, net

    8,874.2



    9,006.6

    Goodwill

    2,023.4



    2,023.7

    Other non-current assets

    68.5



    60.8

    Deferred income taxes

    46.6



    46.7

    Operating lease right-of-use assets

    52.0



    55.2

    Total assets

    $                 12,504.7



    $              12,706.8

    LIABILITIES AND SHAREHOLDERS' EQUITY







    Current liabilities:







    Accounts payable

    $                      102.7



    $                   144.1

    Accrued compensation

    85.8



    126.5

    Accrued expenses and other current liabilities

    365.1



    315.2

    Current portion of deferred revenues

    1,010.1



    983.1

    Current portion of operating lease liability

    24.3



    24.4

    Liabilities held for sale

    26.8



    6.7

    Total current liabilities

    1,614.8



    1,600.0

    Long-term debt

    4,637.9



    4,721.1

    Non-current portion of deferred revenues

    17.7



    38.7

    Other non-current liabilities

    41.7



    41.9

    Deferred income taxes

    246.2



    249.6

    Operating lease liabilities

    58.0



    63.2

    Total liabilities

    6,616.3



    6,714.5

    Commitments and contingencies







    Shareholders' equity:







    Preferred Shares, no par value; 14.4 shares authorized; 5.25% Mandatory Convertible Preferred Shares, Series A, 14.4 shares issued and outstanding as of both March 31, 2024 and December 31, 2023

    1,392.6



    1,392.6

    Ordinary Shares, no par value; unlimited shares authorized; 668.2(1) and 666.1 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively

    11,747.4



    11,740.5

    Accumulated other comprehensive loss

    (512.3)



    (495.3)

    Accumulated deficit

    (6,739.3)



    (6,645.5)

    Total shareholders' equity

    5,888.4



    5,992.3

    Total liabilities and shareholders' equity

    $                 12,504.7



    $              12,706.8

    (1) Refer to the Condensed Consolidated Statements of Changes in Equity within the 10-Q.

     

    Condensed Consolidated Statements of Operations (Unaudited)





    Three Months Ended March 31,

    (In millions, except per share data)

    2024



    2023

    Revenues

    $                      621.2



    $                      629.1

    Operating expenses:







    Cost of revenues

    217.8



    229.7

    Selling, general and administrative costs

    191.9



    194.8

    Depreciation and amortization

    179.4



    172.6

    Restructuring

    9.5



    9.4

    Other operating expense (income), net

    17.6



    (32.0)

    Total operating expenses

    616.2



    574.5

    Income (loss) from operations

    5.0



    54.6

    Fair value adjustment of warrants

    (5.2)



    1.1

    Interest expense, net

    70.2



    73.6

    Income (loss) before income taxes

    (60.0)



    (20.1)

    Provision (benefit) for income taxes

    15.0



    (63.6)

    Net income (loss)

    (75.0)



    43.5

    Dividends on preferred shares

    18.8



    18.8

    Net income (loss) attributable to ordinary shares

    $                      (93.8)



    $                        24.7









    Per share:







    Basic

    $                      (0.14)



    $                        0.04

    Diluted

    $                      (0.14)



    $                        0.04









    Weighted average shares used to compute earnings per share:







    Basic

    666.9



    674.8

    Diluted

    666.9



    679.3

     

    Condensed Consolidated Statements of Cash Flows (Unaudited)





    Three Months Ended March 31,

    (In millions)

    2024



    2023

    Cash Flows From Operating Activities







    Net income (loss)

    $                     (75.0)



    $                       43.5

    Adjustments to reconcile net income (loss) to net cash provided by operating activities:







    Depreciation and amortization

    179.4



    172.6

    Share-based compensation

    14.9



    40.7

    Gain on legal settlement

    —



    (49.4)

    Amortization of debt issuance costs

    4.7



    5.1

    Other operating activities

    10.1



    9.7

    Changes in operating assets and liabilities:







    Accounts receivable

    74.8



    42.3

    Prepaid expenses

    (11.8)



    (21.7)

    Other assets

    (3.0)



    13.7

    Accounts payable

    (37.3)



    (0.1)

    Accrued expenses and other current liabilities

    (10.0)



    (33.0)

    Deferred revenues

    31.0



    85.5

    Operating leases, net

    (1.8)



    (2.0)

    Other liabilities

    0.2



    (79.4)

    Net cash provided by operating activities

    176.2



    227.5

    Cash Flows From Investing Activities







    Capital expenditures

    (64.4)



    (59.3)

    Payments for acquisitions

    —



    (1.1)

    Net cash provided by (used for) investing activities

    (64.4)



    (60.4)

    Cash Flows From Financing Activities







    Principal payments on term loan

    (47.4)



    (125.0)

    Payment of debt issuance costs and discounts

    (20.0)



    —

    Cash dividends on preferred shares

    (18.9)



    (18.9)

    Payments related to finance lease

    (0.3)



    (0.2)

    Payments related to tax withholding for stock-based compensation

    (8.6)



    (7.5)

    Net cash provided by (used for) financing activities

    (95.2)



    (151.6)

    Effects of exchange rates

    (6.3)



    2.0

    Net change in cash and cash equivalents, including restricted cash

    $                       10.3



    $                       17.5

    Cash and cash equivalents, including restricted cash, beginning of period

    370.7



    356.8

    Cash and cash equivalents, including restricted cash, end of period(1)

    $                     381.0



    $                     374.3

    (1) Includes $19.2 of cash that was reclassified to current assets held for sale in the Condensed Consolidated Balance Sheet as of March 31, 2024.

    Supplemental Revenues Information

    Annualized contract value ("ACV") represents the annualized value for the next 12 months of subscription-based client license agreements, assuming that all expiring license agreements during that period are renewed at their current price level. Our ACV was $1,583.3 and $1,555.2 as of March 31, 2024 and 2023, respectively, which corresponds to an increase of 1.8%. The increase in ACV was primarily due to the impact of price increases.

    The following tables present our revenues by type and by segment for the periods indicated, as well as the drivers of the variances between periods, including as a percentage of such revenues.



    Three Months Ended

    March 31,



    Change



    Percentage of Change

    (In millions, except percentages); (unaudited)

    2024



    2023



    $

    %



    Acquisitions

    Disposals

    FX

    Impact

    Organic

    Subscription revenues

    $       403.1



    $      393.2



    $           9.9

    2.5 %



    0.1 %

    — %

    — %

    2.4 %

    Re-occurring revenues

    102.5



    107.7



    (5.2)

    (4.8) %



    — %

    — %

    0.3 %

    (5.1) %

    Transactional and other revenues

    115.6



    128.2



    (12.6)

    (9.8) %



    0.1 %

    0.9 %

    0.6 %

    (11.4) %

    Revenues

    $       621.2



    $      629.1



    $         (7.9)

    (1.3) %



    — %

    0.2 %

    0.2 %

    (1.7) %







    Three Months Ended

    March 31,



    Change



    Percentage of Change

    (In millions, except percentages); (unaudited)

    2024



    2023



    $

    %



    Acquisitions

    Disposals

    FX

    Impact

    Organic

    Academia & Government

    $       317.7



    $      314.7



    $           3.0

    1.0 %



    — %

    — %

    0.4 %

    0.6 %

    Intellectual Property

    200.9



    209.1



    (8.2)

    (3.9) %



    — %

    0.5 %

    0.1 %

    (4.5) %

    Life Sciences & Healthcare

    102.6



    105.3



    (2.7)

    (2.6) %



    0.3 %

    — %

    (0.1) %

    (2.8) %

    Revenues

    $       621.2



    $      629.1



    $         (7.9)

    (1.3) %



    — %

    0.2 %

    0.2 %

    (1.7) %

     

    Reconciliations to Certain Non-GAAP Measures

    Adjusted EBITDA and Adjusted EBITDA margin

    Adjusted EBITDA represents Net income (loss) before the Provision (benefit) for income taxes, Depreciation and amortization, and Interest expense, net, adjusted to exclude acquisition and/or disposal-related transaction costs, share-based compensation, mandatory convertible preferred share ("MCPS") dividend expense, unrealized foreign currency gains/losses, restructuring expenses, non-operating income and/or expense, the impact of certain non-cash fair value adjustments on financial instruments, legal settlements, impairments, and other items that are included in Net income (loss) for the period that we do not consider indicative of our ongoing operating performance. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues.

    The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the three months ended March 31, 2024 and 2023 and reconciles these non-GAAP measures to our Net income (loss) for the same periods:



    Three Months Ended March 31,

    (In millions, except percentages); (unaudited)

    2024



    2023

    Net income (loss) attributable to ordinary shares

    $                (93.8)



    $                  24.7

    Dividends on preferred shares

    18.8



    18.8

    Net income (loss)

    (75.0)



    43.5

    Provision (benefit) for income taxes

    15.0



    (63.6)

    Depreciation and amortization

    179.4



    172.6

    Interest expense, net

    70.2



    73.6

    Transaction related costs

    4.4



    1.7

    Share-based compensation expense

    15.4



    41.2

    Restructuring

    9.5



    9.4

    Fair value adjustment of warrants

    (5.2)



    1.1

    Other(1)

    22.6



    (26.8)

    Adjusted EBITDA

    $                236.3



    $                252.7

    Adjusted EBITDA margin

    38.0 %



    40.2 %



    (1) Primarily reflects the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. The three months ended March 31, 2024 also includes a $15.8 loss on a small divestiture. The three months ended March 31, 2023 also includes a $49.4 gain on legal settlement.

    Adjusted net income and Adjusted diluted EPS

    Adjusted net income is calculated using Net income (loss), adjusted to exclude acquisition and/or disposal-related transaction costs (such costs include net income from continuing operations before the provision for income taxes, depreciation and amortization, and interest income and expense from the divested business), amortization related to acquired intangible assets, share-based compensation, MCPS dividend expense, unrealized foreign currency gains/losses, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, legal settlements, impairments, and other items that are included in net income (loss) for the period that we do not consider indicative of our ongoing operating performance and the income tax impact of any adjustments.

    Adjusted diluted EPS is calculated by dividing Adjusted net income by Adjusted diluted weighted average shares for the period. The Adjusted diluted weighted average shares assumes that all instruments in the calculation are dilutive.

    The following table presents our calculation of Adjusted net income and Adjusted diluted EPS for the three months ended March 31, 2024 and 2023 and reconciles these non-GAAP measures to our Net income (loss) and diluted EPS for the same periods:



    Three Months Ended March 31,



    2024



    2023

    (In millions, except per share amounts); (unaudited)

    Amount



    Per Share



    Amount



    Per Share

    Net income (loss) attributable to ordinary shares

    (93.8)



    (0.14)



    24.7



    0.04

    Dividends on preferred shares

    18.8



    0.03



    18.8



    0.03

    Net income (loss) and EPS

    (75.0)



    (0.11)



    43.5



    0.06

    Transaction related costs

    4.4



    0.01



    1.7



    —

    Share-based compensation expense

    15.4



    0.02



    41.2



    0.06

    Amortization related to acquired intangible assets

    138.5



    0.21



    144.4



    0.21

    Restructuring

    9.5



    0.01



    9.4



    0.01

    Fair value adjustment of warrants

    (5.2)



    (0.01)



    1.1



    —

    Other(1)

    22.6



    0.02



    (26.8)



    (0.04)

    Income tax impact of related adjustments

    (6.7)



    (0.01)



    (83.6)



    (0.12)

    Adjusted net income and Adjusted diluted EPS

    $              103.5



    $                 0.14



    $              130.9



    $                0.18

    Adjusted weighted-average ordinary shares (diluted)

    727.6



    734.7

    (1) Primarily reflects the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. The three months ended March 31, 2024 also includes a $15.8 loss on a small divestiture. The three months ended March 31, 2023 also includes a $49.4 gain on legal settlement.

    Free cash flow

    Free cash flow is calculated using Net cash provided by operating activities less Capital expenditures. The following table reconciles this non-GAAP measure to Net cash provided by operating activities:



    Three Months Ended March 31,

    (In millions); (unaudited)

    2024



    2023

    Net cash provided by operating activities

    $                    176.2



    $                    227.5

    Capital expenditures

    (64.4)



    (59.3)

    Free cash flow

    $                    111.8



    $                    168.2

    Reconciliations to Certain Non-GAAP Measures - 2024 Outlook

    Adjusted EBITDA and Adjusted EBITDA margin

    The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the 2024 outlook and reconciles these non-GAAP measures to our Net income (loss) for the same period:



    Year Ending December 31, 2024

    (Forecasted)

    (In millions); (unaudited)

    Low



    High

    Net income (loss) attributable to ordinary shares

    $                 (160)



    $                 (100)

    Dividends on preferred shares(1)

    35



    35

    Net income (loss)

    (125)



    (65)

    Provision (benefit) for income taxes

    60



    60

    Depreciation and amortization

    720



    720

    Interest expense, net

    280



    280

    Restructuring(2)

    10



    10

    Transaction related costs

    15



    15

    Fair value adjustment of warrants

    (5)



    (5)

    Share-based compensation expense

    80



    80

    Other

    20



    20

    Adjusted EBITDA

    $                1,055



    $                1,115

    Adjusted EBITDA margin

    41 %



    42 %

    (1) Dividends on our MCPS are payable quarterly at an annual rate of 5.25% of the liquidation preference of $100 per share. For the purposes of calculating net loss attributable to Clarivate, we have excluded the accrued and anticipated MCPS dividends.

    (2) Reflects restructuring costs expected to be incurred in 2024 associated with the Segment Optimization restructuring program.

    Adjusted diluted EPS

    The following table presents our calculation of Adjusted diluted EPS for the 2024 outlook and reconciles this non-GAAP measure to our per share Net income (loss) for the same period:



    Year Ending December 31, 2024

    (Forecasted)



    Low



    High

    (Unaudited)

    Per Share



    Per Share

    Net income (loss) attributable to ordinary shares

    $                    (0.24)



    $                    (0.14)

    Dividends on preferred shares(1)

    0.05



    0.05

    Net income (loss)

    (0.19)



    (0.09)

    Restructuring(2)

    0.01



    0.01

    Transaction related costs

    0.02



    0.02

    Share-based compensation expense

    0.11



    0.11

    Amortization related to acquired intangible assets

    0.75



    0.75

    Mark to market adjustment on financial instruments

    (0.01)



    (0.01)

    Other

    0.05



    0.05

    Income tax impact of related adjustments

    (0.04)



    (0.04)

    Adjusted diluted EPS

    $                      0.70



    $                      0.80

    Adjusted weighted-average ordinary shares (diluted)(3)

    730 million

    (1-2) Refer to associated line item descriptions provided for the Adjusted EBITDA outlook reconciliation table above.

    (3) For the purposes of calculating Adjusted diluted EPS, we have excluded the accrued and anticipated MCPS dividends and assumed the "if-converted" method of share dilution.

    Free cash flow

    The following table presents our calculation of Free cash flow for the 2024 outlook and reconciles this non-GAAP measure to our Net cash provided by operating activities for the same period:



    Year Ending December 31, 2024

    (Forecasted)

    (In millions); (unaudited)

    Low



    High

    Net cash provided by operating activities

    $                       685



    $                       765

    Capital expenditures

    (265)



    (265)

    Free cash flow

    $                       420



    $                       500

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-reports-first-quarter-2024-results-302139141.html

    SOURCE Clarivate Plc

    Get the next $CLVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLVT

    DatePrice TargetRatingAnalyst
    1/8/2026$3.60Buy → Neutral
    Goldman
    12/17/2025$3.00Equal-Weight → Underweight
    Morgan Stanley
    9/3/2025Peer Perform
    Wolfe Research
    7/18/2025$4.50Buy → Hold
    Jefferies
    11/6/2024Outperform → Mkt Perform
    William Blair
    12/15/2023$8.00Equal Weight → Underweight
    Wells Fargo
    10/16/2023$10.00 → $8.50Hold → Buy
    Jefferies
    9/8/2023$8.00 → $7.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $CLVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cornick Kenneth L. bought $345,000 worth of Ordinary Shares (100,000 units at $3.45) (SEC Form 4)

    4 - CLARIVATE PLC (0001764046) (Issuer)

    11/13/25 8:51:35 AM ET
    $CLVT
    EDP Services
    Technology

    Director Cornick Kenneth L. bought $2,482,000 worth of Ordinary Shares (725,000 units at $3.42) (SEC Form 4)

    4 - CLARIVATE PLC (0001764046) (Issuer)

    11/3/25 7:20:21 PM ET
    $CLVT
    EDP Services
    Technology

    Director Snyder Andrew Miles bought $4,861,800 worth of Ordinary Shares (1,460,000 units at $3.33) (SEC Form 4)

    4 - CLARIVATE PLC (0001764046) (Issuer)

    11/3/25 5:16:01 PM ET
    $CLVT
    EDP Services
    Technology

    $CLVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Clarivate downgraded by Goldman with a new price target

    Goldman downgraded Clarivate from Buy to Neutral and set a new price target of $3.60

    1/8/26 8:37:08 AM ET
    $CLVT
    EDP Services
    Technology

    Clarivate downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Clarivate from Equal-Weight to Underweight and set a new price target of $3.00

    12/17/25 8:52:26 AM ET
    $CLVT
    EDP Services
    Technology

    Wolfe Research initiated coverage on Clarivate

    Wolfe Research initiated coverage of Clarivate with a rating of Peer Perform

    9/3/25 8:37:02 AM ET
    $CLVT
    EDP Services
    Technology

    $CLVT
    SEC Filings

    View All

    Clarivate Plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CLARIVATE PLC (0001764046) (Filer)

    2/3/26 8:24:37 AM ET
    $CLVT
    EDP Services
    Technology

    Clarivate Plc filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - CLARIVATE PLC (0001764046) (Filer)

    2/2/26 7:42:36 AM ET
    $CLVT
    EDP Services
    Technology

    SEC Form S-3ASR filed by Clarivate Plc

    S-3ASR - CLARIVATE PLC (0001764046) (Filer)

    11/4/25 7:53:21 AM ET
    $CLVT
    EDP Services
    Technology

    $CLVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Snyder Andrew Miles was granted 15,344 units of Ordinary Shares and covered exercise/tax liability with 479 units of Ordinary Shares, increasing direct ownership by 8% to 192,316 units (SEC Form 4)

    4 - CLARIVATE PLC (0001764046) (Issuer)

    1/5/26 5:21:54 PM ET
    $CLVT
    EDP Services
    Technology

    Director Cornick Kenneth L. covered exercise/tax liability with 2,399 units of Ordinary Shares and was granted 6,362 units of Ordinary Shares, increasing direct ownership by 12% to 36,674 units (SEC Form 4)

    4 - CLARIVATE PLC (0001764046) (Issuer)

    1/5/26 5:21:13 PM ET
    $CLVT
    EDP Services
    Technology

    Director Bomba Jane L Okun was granted 8,607 units of Ordinary Shares and covered exercise/tax liability with 243 units of Ordinary Shares, increasing direct ownership by 4% to 229,522 units (SEC Form 4)

    4 - CLARIVATE PLC (0001764046) (Issuer)

    1/5/26 5:20:21 PM ET
    $CLVT
    EDP Services
    Technology

    $CLVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Impactive Capital Nominates Four Candidates to WEX Board

    Contends Board Level Change is Required to Address Alarming Share Price Underperformance, Culture of Entrenchment and Widening Valuation Gap Versus Its Closest Peer Nominees Kurt Adams, Ellen Alemany, Ken Cornick and Lauren Taylor Wolfe Each Bring an Owner's Perspective and the Relevant Industry Experience to Strengthen Strategic Oversight, Enhance Capital Allocation and Improve Operational Performance Nominees Have Demonstrated Conviction in WEX's Value Potential and Personally Purchased More Shares Than the Entire Incumbent Board Over the Past Nine Years Impactive Capital, LP, ("Impactive" or "we") together with its affiliates, one of the largest shareholders of WEX Inc. (NYSE:WEX)

    2/9/26 8:00:00 AM ET
    $ADP
    $CLVT
    $CPAY
    Diversified Commercial Services
    Industrials
    EDP Services
    Technology

    Clarivate Webinar "Intelligence Amplified in the Age of AI" Highlights How Trusted, Proprietary Data Powers Next‑Generation Innovation

    LONDON, Feb. 3, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of a video webinar, Intelligence Amplified in the Age of AI, an in‑depth session exploring how Clarivate is leveraging artificial intelligence to  reshape research, innovation, and decision‑making across the scientific, academic, intellectual property, and life sciences ecosystems. Hosted by Matti Shem Tov, Chief Executive Officer of Clarivate, the webinar unveils how Clarivate is applying cutting-edge AI technology to amplify the

    2/3/26 8:00:00 AM ET
    $CLVT
    EDP Services
    Technology

    Clarivate Announces Full Redemption of Remaining $100 Million Senior Secured Notes Due 2026 and Provides Update on Capital Allocation Activities

    LONDON, Feb. 2, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that its subsidiary, Camelot Finance S.A., has redeemed the remaining $100 million aggregate principal amount of its 4.50% senior secured notes due 2026, originally issued on October 31, 2019 (the "2026 Notes"). The 2026 Notes were redeemed on January 30, 2026 (the "Redemption Date") at a cash redemption price equal to 100% of the remaining principal amount, or $100 million, plus accrued and unpaid interest through the Redemption Date. With

    2/2/26 7:30:00 AM ET
    $CLVT
    EDP Services
    Technology

    $CLVT
    Leadership Updates

    Live Leadership Updates

    View All

    VideoAmp Expands Board with Former Tech and Data Industry Leaders Jonathan Gear and Sari Granat

    Seasoned executives from Clarivate, IHS Markit and Chainalysis join to guide next-phase innovation and scaling at VideoAmp VideoAmp, a leading advertising technology company, today announced the appointment of Jonathan Gear and Sari Granat to its Board of Directors. Gear and Granat bring extensive leadership experience across information services, SaaS, analytics, and global technology, strengthening VideoAmp's mission to modernize measurement and deliver higher fidelity, outcome-based currency for the industry. Jonathan Gear most recently served as Chief Executive Officer of Clarivate (NYSE:CLVT), a global information and analytics company, where he led a strategic repositioning to drive

    12/2/25 9:00:00 AM ET
    $AIZ
    $CLVT
    $INFO
    Property-Casualty Insurers
    Finance
    EDP Services
    Technology

    Clarivate Announces Maroun S. Mourad as President, Intellectual Property

    LONDON, July 30, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that Maroun S. Mourad will join the Company as President of the Intellectual Property (IP) segment, effective September 8, 2025. Maroun most recently served as President of the Claims Solutions division of Verisk Analytics Inc. He succeeds Gordon Samson, who will retire at the end of 2025 after a high-impact career in the IP industry, spending five years as the Chief Operating Officer at CPA Global, before joining the Clarivate executive team, most recently as the President of the IP segment.

    7/30/25 6:01:00 AM ET
    $CLVT
    EDP Services
    Technology

    Clarivate Appoints Henry Levy as President, Life Sciences & Healthcare

    Concludes the appointments for business leaders of its three market segments LONDON, April 26, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, announced today that it has appointed Henry Levy as President, Life Sciences & Healthcare, effective May 1, 2023. Henry joins from Veeva Systems, a global leader in cloud software for the life sciences industry, where he most recently served as President, Global R&D and Quality, with responsibility for driving sales across the segment. Jonathan Gear,

    4/26/23 7:00:00 AM ET
    $CLVT
    EDP Services
    Technology

    $CLVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clarivate Plc

    SC 13G/A - CLARIVATE PLC (0001764046) (Subject)

    12/5/24 10:02:09 AM ET
    $CLVT
    EDP Services
    Technology

    SEC Form SC 13G filed by Clarivate Plc

    SC 13G - CLARIVATE PLC (0001764046) (Subject)

    11/13/24 4:18:30 PM ET
    $CLVT
    EDP Services
    Technology

    SEC Form SC 13D/A filed by Clarivate Plc (Amendment)

    SC 13D/A - CLARIVATE PLC (0001764046) (Subject)

    3/4/24 9:01:44 AM ET
    $CLVT
    EDP Services
    Technology

    $CLVT
    Financials

    Live finance-specific insights

    View All

    Impactive Capital Nominates Four Candidates to WEX Board

    Contends Board Level Change is Required to Address Alarming Share Price Underperformance, Culture of Entrenchment and Widening Valuation Gap Versus Its Closest Peer Nominees Kurt Adams, Ellen Alemany, Ken Cornick and Lauren Taylor Wolfe Each Bring an Owner's Perspective and the Relevant Industry Experience to Strengthen Strategic Oversight, Enhance Capital Allocation and Improve Operational Performance Nominees Have Demonstrated Conviction in WEX's Value Potential and Personally Purchased More Shares Than the Entire Incumbent Board Over the Past Nine Years Impactive Capital, LP, ("Impactive" or "we") together with its affiliates, one of the largest shareholders of WEX Inc. (NYSE:WEX)

    2/9/26 8:00:00 AM ET
    $ADP
    $CLVT
    $CPAY
    Diversified Commercial Services
    Industrials
    EDP Services
    Technology

    Clarivate to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026

    LONDON, Jan. 28, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the fourth quarter and full year 2025 before the market opens on Tuesday, February 24, 2026. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Tuesday, February 24, 2026 to review the results. The webcast is o

    1/28/26 8:00:00 AM ET
    $CLVT
    EDP Services
    Technology

    Clarivate Reports Third Quarter 2025 Results

    — Continued acceleration of organic ACV — — Raises 2025 Revenues Outlook — — Repurchased 11.7 million ordinary shares and repaid $100 million of debt in the third quarter — LONDON, Oct. 29, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2025. "The third quarter demonstrated continued improved financial and operational performance, underscoring the effectiveness of our Value Creation Plan and the increased focus, growth and i

    10/29/25 6:00:00 AM ET
    $CLVT
    EDP Services
    Technology